28.01

1.30% 0.36

After Hours: 28.01

Enliven Therapeutics Inc (ELVN)

Overview News Price History Option Chain Financials Discussions Forecast

Enliven Therapeutics Inc stock is traded at $28.01, with a volume of 226.19K. It is up +1.30% in the last 24 hours and up +1.74% over the past month. Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.

Previous Close:

$27.65

Open:

$27.55

24h Volume:

226.19K

Relative Volume:

0.99

Market Cap:

$1.32B

Revenue:

Net Income/Loss:

$-71.58M

P/E Ratio:

-22.57

EPS:

-1.2413

Net Cash Flow:

$-61.42M

1W Performance:

-1.79%

1M Performance:

+1.74%

6M Performance:

+23.66%

1Y Performance:

+115.46%

1-Day Range:

$27.02

$28.04

1-Week Range:

$26.91

$29.09

52-Week Range:

$9.80

$30.03

Enliven Therapeutics Inc Stock (ELVN) Company Profile

Name

Enliven Therapeutics Inc

Sector

Healthcare (1181)

Industry

Biotechnology (671)

Phone

720-647-8519

Address

6200 LOOKOUT ROAD, BOULDER

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

ELVN's Discussions on Twitter

Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-29-23	Initiated	Jefferies	Buy

Enliven Therapeutics Inc Stock (ELVN) Latest News

Oct 31, 2024

Jones Trading Initiates Coverage of Enliven Therapeutics (ELVN) with Buy Recommendation - MSN

Oct 31, 2024

Enliven Therapeutics CFO Benjamin Hohl sells shares worth $178,484 By Investing.com - Investing.com South Africa

Oct 31, 2024

Oct 30, 2024

Enliven Therapeutics CFO Benjamin Hohl sells shares worth $178,484 - Investing.com

Oct 30, 2024

Oct 27, 2024

Enliven Therapeutics (ELVN) Price Target Increased by 10.75% to 35.02 - MSN

Oct 27, 2024

Oct 23, 2024

Enliven Therapeutics CFO sells $24,422 in stock By Investing.com - Investing.com Australia

Oct 23, 2024

Oct 22, 2024

Enliven Therapeutics CFO sells $24,422 in stock - Investing.com

Oct 22, 2024

Enliven Therapeutics chief medical officer sells $24,482 in stock By Investing.com - Investing.com Canada

Oct 22, 2024

Enliven Therapeutics chief medical officer sells $24,482 in stock - Investing.com India

Oct 22, 2024

Enliven Therapeutics COO Anish Patel sells $21,482 in stock - Investing.com

Oct 22, 2024

Enliven Therapeutics COO Anish Patel sells $21,482 in stock By Investing.com - Investing.com Australia

Oct 22, 2024

Enliven Therapeutics' chief scientific officer sells $25,412 in stock By Investing.com - Investing.com Australia

Oct 22, 2024

Enliven Therapeutics CEO Kintz sells $27,722 in stock - Investing.com

Oct 22, 2024

Enliven Therapeutics' chief scientific officer sells $25,412 in stock - Investing.com India

Oct 22, 2024

Enliven Therapeutics director Heyman sells $47,104 in stock By Investing.com - Investing.com Australia

Oct 22, 2024

Enliven Therapeutics CEO Kintz sells $27,722 in stock By Investing.com - Investing.com Australia

Oct 22, 2024

Enliven Therapeutics director Heyman sells $47,104 in stock - Investing.com India

Oct 22, 2024

Anish Patel Sells 716 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock - MarketBeat

Oct 22, 2024

Oct 21, 2024

When (ELVN) Moves Investors should Listen - Stock Traders Daily

Oct 21, 2024